Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Thitima Kongnakorn1 Evidence Synthesis, Modeling and Communication, Evidera, London, UKView further author information

Murtuza Bharmal2 Global Evidence and Value Development, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germany), Rockland, MA, USACorrespondence[email protected]
View further author information

Mairead Kearney3 Global Evidence and Value Development, Merck KGaA, Darmstadt, GermanyView further author information

Hemant Phatak4 US Health Economics and Outcomes Research, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germany), Rockland, MA, USAView further author information

Agnes Benedict5 Evidence Synthesis, Modeling and Communication, Evidera, Budapest, HungaryView further author information

Abhijeet Bhanegaonkar4 US Health Economics and Outcomes Research, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germany), Rockland, MA, USAView further author information

Matthew Galsky6 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.